[go: up one dir, main page]

MX2015014958A - Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma. - Google Patents

Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.

Info

Publication number
MX2015014958A
MX2015014958A MX2015014958A MX2015014958A MX2015014958A MX 2015014958 A MX2015014958 A MX 2015014958A MX 2015014958 A MX2015014958 A MX 2015014958A MX 2015014958 A MX2015014958 A MX 2015014958A MX 2015014958 A MX2015014958 A MX 2015014958A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
same
salts
triazolone derivatives
novel triazolone
Prior art date
Application number
MX2015014958A
Other languages
English (en)
Inventor
Dong-Hoon Lee
Tae-Dong Han
Eun-Hye Jung
Chung-Ho Yi
Byoung-Moon Lee
Yoo-Hoi Park
Jong-Ho Kang
Na-Yeon Yang
Do-Hoon Kim
Kwan-Hoon Hyun
Kaap-Joo Park
Chun-Hoo Lee
Su-Youn Nam
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2015014958A publication Critical patent/MX2015014958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un derivado de triazolona o su sal farmacéuticamente aceptable, un procedimiento para la preparación de los mismos, y una composición farmacéutica que comprende a la misma. El derivado de triazolona o su sal farmacéuticamente aceptable pueden activar eficazmente al GPR119 y, por lo tanto, pueden aplicarse de manera útil para la prevención o tratamiento de la diabetes mellitus.
MX2015014958A 2013-04-25 2014-04-22 Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma. MX2015014958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130045985 2013-04-25
PCT/KR2014/003480 WO2014175621A1 (en) 2013-04-25 2014-04-22 Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
MX2015014958A true MX2015014958A (es) 2016-03-07

Family

ID=51792116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014958A MX2015014958A (es) 2013-04-25 2014-04-22 Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.

Country Status (11)

Country Link
US (1) US9663495B2 (es)
EP (1) EP2989093A4 (es)
JP (1) JP2016517862A (es)
KR (1) KR101720937B1 (es)
CN (1) CN105143210A (es)
AU (1) AU2014258128A1 (es)
BR (1) BR112015026631A2 (es)
CA (1) CA2910131A1 (es)
MX (1) MX2015014958A (es)
RU (1) RU2015150071A (es)
WO (1) WO2014175621A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192532A1 (en) 2008-07-16 2013-08-30 Tela Innovations Inc Methods for cell phasing and placement in dynamic array architecture and implementation of the same
EP3085700B1 (en) 2013-12-20 2018-10-31 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Novel piperidine carboxamide compound, preparation method, and usage thereof
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
UY38929A (es) * 2019-10-21 2021-05-31 Korea Res Inst Chemical Tech Compuestos de nicotinamida y composición herbicida que comprenden lo mismo
GB2598624A (en) * 2020-09-07 2022-03-09 Lorico Aurelio Use of triazole analogues for inhibition of a tripartite VOR protein complex in multicellular organisms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101171211B1 (ko) * 2004-03-10 2012-08-07 얀센 파마슈티카 엔.브이. Ｍｔｐ를 저해하는 5-원 헤테로사이클에 의해 치환된 아릴 피페리딘 또는 피페라진
EP2121661A1 (en) * 2006-12-20 2009-11-25 Merck & Co., Inc. Bipiperidinyl compounds, compositions containing such compounds and methods of treatment
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease

Also Published As

Publication number Publication date
CN105143210A (zh) 2015-12-09
BR112015026631A2 (pt) 2017-07-25
AU2014258128A1 (en) 2015-10-29
EP2989093A4 (en) 2016-12-14
RU2015150071A (ru) 2017-05-29
JP2016517862A (ja) 2016-06-20
WO2014175621A1 (en) 2014-10-30
KR101720937B1 (ko) 2017-03-29
US20160068515A1 (en) 2016-03-10
EP2989093A1 (en) 2016-03-02
US9663495B2 (en) 2017-05-30
CA2910131A1 (en) 2014-10-30
KR20140127758A (ko) 2014-11-04

Similar Documents

Publication Publication Date Title
PH12018502742A1 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12015502091A1 (en) Cdc7 inhibitors
MX2015014958A (es) Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3069720A4 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
HUP1400075A2 (hu) Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3156055A4 (en) Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
HUP1500618A2 (en) Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
PL3212640T3 (pl) Związek mający aktywność agonistyczną GPR119, sposób jego wytwarzania i kompozycja farmaceutyczna zawierająca go jak skuteczny składnik
EP3303320A4 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
GB2543709A (en) Pharmaceutical agent
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
PH12016500980A1 (en) Amide derivatives for gpr119 agonist
WO2016020408A3 (en) Compounds for preventing ototoxicity
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors
WO2014053962A3 (en) Compositions and methods for treatment of diabetes and pre-diabetes
WO2019203748A3 (en) The composition comprising raloxifene with at least one antipsychotic agent
CR20190161A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terpéutico del mismo
HK1230926A1 (en) Pharmaceutical agent
UA88315U (en) Antibacterial composition
HUP1400084A2 (hu) Dabigatran és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
EP3015106A4 (en) Composition for preventing or treating renal diseases, containing dpp-iv inhibitor